The Board:

- 1. Approves the incremental funding recommended for each country (or, as the case may be, regional) disease component, and its constituent grants, as listed in Tables 1a and 1b of Section IV to GF/B34/ER02 (collectively, "Table 1");
- 2. Acknowledges each country (or, as the case may be, regional) disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;
- 3. Approves the reinvestment of within-allocation efficiencies for the Zanzibar TB/HIV grant and its resultant total program budget, as listed in Table 2 of Section IV to GF/B34/ER02;
- *4.* Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country (or, as the case may be, regional) disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and
- 5. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.

N	Country	Disease component	Grant name	Grant end date	Currency	Recommended budget (incl. cash & disbursements)	Total program budget	Existing funding	Increment al amount for Board approval	Recommended total incremental funding	Incentive funding included in total incremental funding	Unfunded quality demand	Domestic commitment
1	Botswana	TB/HIV	BWA- C- ACHAP	31 December 2018	US\$	16,798,970	27,043,8	0	16,798,970	26,614,280	3,478,787	7,380,889	HIV: 363 million TB: 60.5 million
			BWA- C- BMOH	31 December 2018	US\$	10,244,837	07	429,527	9,815,310				
2	Chad	Malaria	TCD- M- UNDP	30 June 2018	€	59,732,391	59,732,3 91	4,744,326	54,988,065	54,988,065	2,506,789	0	19,155,904
3	Djibouti	Malaria	DJI-M- UNDP	31 December 2017	US\$	7,794,954	7,794,95 4	0	7,794,954	7,794,954	N/A	0	4 million
4	Djibouti	TB/HIV	DJI-C- UNDP	31 December 2017	US\$	9,019,598	9,019,59 8	405,148	8,614,450	8,614,450	N/A	0	HIV: 3.6 million TB: 2.8 million
5	Haiti	Malaria	HTI-M- PSI	31 December 2017	US\$	17,305,284	17,305,2 84	1,624,049	15,681,235	15,681,235	N/A	7,454,346	8,185,375
6	Indonesia	TB/HIV	IDN-H- MOH	31 December 2017	US\$	37,873,918	170,824,7 18	19,534,896	18,339,022	107,497,461	27,761,979	47,158,874	HIV: 160 million TB: 190 million
			IDN-H- NAC	31 December 2017	US\$	20,474,258		6,609,743	13,864,515				
			IDN-H- SPIRIT I	31 December 2017	US\$	24,287,653		1,087,275	23,200,378				

			IDN-T- MOH	31 December 2017	US\$	66,363,204		31,268,111	35,095,093				
			IDN-T- AISYIY A	31 December 2017	US\$	21,825,685		4,827,232	16,998,453				
7	Mali <sup>1</sup>	TB/HIV	MLI-H- UNDP	31 December 2017	€	50,270,153	50,270,15 3	37,414,695	12,855,458	12,855,458	N/A	0	HIV: 11.2 million
8	Paraguay	Malaria	PRY- M-OIM	31 December 2018	US\$	2,782,936	2,782,93 6	0	2,782,936	2,782,936	N/A	0	19.8 million
9	Sao Tome and Principe	Malaria	STP-M- UNDP	31 December 2017	US\$	5,851,908	5,851,90 8	1,460,978	4,390,930	4,390,930	N/A	0	1,907,128
10	Senegal	HSS	SEN-S- MOH	31 December 2017	€	4,386,050	4,386,05 0	0	4,386,050	4,386,050	N/A	0	135,287,250

<sup>&</sup>lt;sup>1</sup> Although Mali submitted a joint TB/HIV concept note as a country with a high rate of TB/HIV confection, the grant presented in this report includes only the HIV treatment component. The TB grant, which underwent integrated grant-making with the HIV grants, will be implemented by a different Principal Recipient and will be reviewed by the GAC at a future meeting. Additionally, a civil society Principal Recipient for the HIV grant focusing on prevention will be reviewed by the GAC early next year.

11	Sierra Leone	TB/HIV	SLE-H- NAS	31 December 2017	US\$	33,194,380	46,660,4 21	27,572,736	5,621,644	17,833,256	14,168,943	10,871,123	HIV: 2.25 million TB: 0.68 million
			SLE-H- MOHS	31 December 2017	US\$	13,466,041		1,254,429	12,211,612				
12	Sri Lanka	HIV/AIDS	LKA- H-FPA	31 December 2018	US\$	5,442,741	10,907,2 92	902,022	4,540,719	8,396,628	N/A	0	16,375,947
			LKA- H- MOH	31 December 2018	US\$	5,464,551		1,608,642	3,855,909				
13	Togo	Malaria	TGO- M-PMT	31 December 2017	€	23,903,520	23,903,5 20	18,877,384	5,026,136	5,026,136	3,402,117	0	7.04 million
14	Tunisia	HIV/AIDS	TUN- H- ONFP	31 December 2018	US\$	11,552,532	11,552,53 2	1,071,949	10,480,583	10,480,583	N/A	672,553	25,311,154

 Table 1b: Secretariat's Funding Recommendation on Additional Funding from the 2014 Allocation (Regional Applicant)

	Country	Disease component	Grant name	Grant end date	Currency	Total program budget	Existing funding	Incremental amount for Board approval	Recommended total incremental funding	Incentive funding included in total incremental funding	Unfunded quality demand	Domestic commitment
1	Southern Africa Regional Coordinating Mechanism	ТВ	QPA-T- WHC	31 December 2017	US\$	29,999,027	356,707	29,642,320	29,642,320	N/A	104,517,892	N/A

## Table 2: Reinvestment of Within-allocation Efficiencies for a Previously-approved Program

Applicant	Grant name	Currency	Approved grant budget	Revised budget for Board approval	Existing funding	Revised existing funding	Incremental funding already approved	Additional incremental funding for Board approval	Revised unfunded quality demand
Zanzibar <sup>2</sup>	QNB-C-MOH	US\$	10,224,371	10,332,417	1,105,518	1,213,564	9,118,853	0	236,246

<sup>&</sup>lt;sup>2</sup> The GAC recommends that the Board approve an increase to the budget amount of the Zanzibar TB/HIV grant QNB-C-MOH. The additional amount requested is within the allocation and represents reinvestment of committed funds under the round 10 grant ZAN-T-MOHSW as well as undisbursed and unused cash funds that were not included in the total budget when the Board approved an incremental amount for the Zanzibar TB/HIV grant on 14 October 2015 (GF/B33/EDP20). The CCM requests to reinvest this amount in unfunded quality demand, in line with the current program and TRP recommendations.